Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
40.79
+0.14 (0.34%)
At close: Apr 10, 2026, 4:00 PM EDT
40.77
-0.02 (-0.05%)
After-hours: Apr 10, 2026, 6:47 PM EDT
Apellis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 17 analysts that cover Apellis Pharmaceuticals stock have a consensus rating of "Hold" and an average price target of $32.71, which forecasts a -19.81% decrease in the stock price over the next year. The lowest target is $18 and the highest is $52.
Price Target: $32.71 (-19.81%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Apellis Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 6 | 6 | 6 | 4 |
| Buy | 7 | 6 | 5 | 5 | 5 | 2 |
| Hold | 9 | 8 | 8 | 8 | 9 | 14 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 21 | 20 | 20 | 20 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Hold Maintains $20 → $41 | Hold | Maintains | $20 → $41 | +0.51% | Apr 2, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Apr 1, 2026 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades $37 → $41 | Buy → Hold | Downgrades | $37 → $41 | +0.51% | Apr 1, 2026 |
| Barclays | Barclays | Hold Maintains $24 → $41 | Hold | Maintains | $24 → $41 | +0.51% | Apr 1, 2026 |
| Raymond James | Raymond James | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Apr 1, 2026 |
Financial Forecast
Revenue This Year
882.48M
from 1.00B
Decreased by -12.08%
Revenue Next Year
1.04B
from 882.48M
Increased by 18.19%
EPS This Year
-1.18
from 0.17
EPS Next Year
-0.26
from -1.18
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.0B | 1.2B | |||
| Avg | 882.5M | 1.0B | |||
| Low | 778.6M | 855.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.1% | 40.4% | |||
| Avg | -12.1% | 18.2% | |||
| Low | -22.4% | -3.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.40 | 1.05 | |||
| Avg | -1.18 | -0.26 | |||
| Low | -2.15 | -1.98 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.